Cargando…

Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity

Programmed death-ligand 1 (PD-L1) and T cell immunoreceptor with Ig and ITIM domains (TIGIT) are two potential targets for cancer immunotherapy, early clinical studies showed the combination therapy of anti-PD-L1 and anti-TIGIT had synergistic efficacy both in the terms of overall response rate (ORR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhong, Zhenwei, Zhang, Mengyao, Ning, Yanan, Mao, Guanchao, Li, Xiaopei, Deng, Qi, Chen, Xiaorui, Zuo, Dongliang, Zhao, Xiangyu, Xie, Ermin, Wang, Huajing, Guo, Lina, Li, Bohua, Xiao, Kai, He, Xiaowen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606248/ https://www.ncbi.nlm.nih.gov/pubmed/36289396 http://dx.doi.org/10.1038/s41598-022-22975-7

Ejemplares similares

PD‐L1/TIGIT bispecific antibody showed survival advantage in animal model
por: Mu, Songlin, et al.
Publicado: (2022)

Discovery of TIGIT inhibitors based on DEL and machine learning
por: Xiong, Feng, et al.
Publicado: (2022)

Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer
por: Peng, Hui, et al.
Publicado: (2022)

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
por: Chu, Xianjing, et al.
Publicado: (2023)

A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers
por: Hosseinkhani, Negar, et al.
Publicado: (2021)

TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020)

Correction: Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
por: Chu, Xianjing, et al.
Publicado: (2023)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
por: Hung, Alice L., et al.
Publicado: (2018)

A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities
por: Cui, Xiaopei, et al.
Publicado: (2021)

PD-1 and TIGIT Are Highly Co-Expressed on CD8(+) T Cells in AML Patient Bone Marrow
por: Xu, Ling, et al.
Publicado: (2021)

The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients
por: Pawłowska, Anna, et al.
Publicado: (2022)

PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma
por: Yang, Zhenlin, et al.
Publicado: (2022)

Dynamic Expressions of TIGIT on Splenic T Cells and TIGIT-Mediated Splenic T Cell Dysfunction of Mice With Chronic Toxoplasma gondii Infection
por: Li, Haoran, et al.
Publicado: (2021)

Increased TIGIT(+)PD‑1(+)CXCR5(‑)CD4(+)T cells are associated with disease activity in rheumatoid arthritis
por: Luo, Qing, et al.
Publicado: (2022)

Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor
por: Zhao, Jingjing, et al.
Publicado: (2023)

The role of apoptosis in bispecific antibody-mediated T-cell cytotoxicity.
por: Kroesen, B. J., et al.
Publicado: (1996)

Bispecific GPC3/PD-1 CAR-T cells for the treatment of HCC
por: Li, Dezhi, et al.
Publicado: (2023)

Computer-aided design of PVR mutants with enhanced binding affinity to TIGIT
por: Zhou, Xiaowen, et al.
Publicado: (2021)

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
por: Grapin, Mathieu, et al.
Publicado: (2019)

TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma
por: Raphael, Itay, et al.
Publicado: (2021)

PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy
por: Simon, Sylvain, et al.
Publicado: (2020)

TIGIT-based immunotherapeutics in lung cancer
por: Patel, Akshay J, et al.
Publicado: (2023)

TIGIT Can Exert Immunosuppressive Effects on CD8(+) T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro
por: Zhang, Changkun, et al.
Publicado: (2020)

DNAM1 and TIGIT balance the T cell response, with low T cell TIGIT expression corresponding to inflammation in psoriatic disease
por: Jacobs, Marleen E, et al.
Publicado: (2020)

CD4(+) T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART
por: Fromentin, Rémi, et al.
Publicado: (2016)

Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia
por: Zhu, Liuluan, et al.
Publicado: (2017)

Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer
por: Weimer, Pauline, et al.
Publicado: (2022)

PD1, CTLA4 and TIGIT Expression on T and NK Cells in Granulomatous Diseases: Sarcoidosis and ANCA-Associated Vasculitis
por: d’Alessandro, Miriana, et al.
Publicado: (2022)

Combined Blockade Of PD-1 and TIGIT is not Sufficient to Improve the Function Of CD8+ T-Cells in Chronic Lymphocytic Leukemia
por: Hatefi, Fatemeh, et al.
Publicado: (2022)

Expression of the immune checkpoint receptor TIGIT in seminoma
por: Hinsch, Andrea, et al.
Publicado: (2019)

Circulating Melanoma Cell Numbers Correlate with TIGIT-Positive Cytotoxic T Cell Counts in Advanced-Stage Melanoma Patients
por: Kamińska, Paula, et al.
Publicado: (2023)

TIGIT as a Promising Therapeutic Target in Autoimmune Diseases
por: Yue, Chenran, et al.
Publicado: (2022)

A pan-cancer analysis revealing the role of TIGIT in tumor microenvironment
por: Wen, Jie, et al.
Publicado: (2021)

Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR
por: Zhou, Xiuman, et al.
Publicado: (2020)

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy
por: Shi, Ning, et al.
Publicado: (2022)

Mechanisms of TIGIT-driven immune suppression in cancer
por: Kurtulus, Sema, et al.
Publicado: (2014)

Update in TIGIT Immune-Checkpoint Role in Cancer
por: Annese, Tiziana, et al.
Publicado: (2022)

TIGIT in Lung Cancer: Potential Theranostic Implications
por: Pescia, Carlo, et al.
Publicado: (2023)

High Plus Low Dose Radiation Strategy in Combination with TIGIT and PD1 Blockade to Promote Systemic Antitumor Responses
por: Barsoumian, Hampartsoum B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_osbhd3kboet8h1s741nipkb8a3